Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

Denise A. Yardley, MD
Published: Tuesday, Aug 02, 2016


Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses unmet treatment needs for patients with HER2-positive breast cancer.

Several developments have been made in the field of HER2-positive breast cancer, particularly with the additions of trastuzumab (Herceptin) and pertuzumab (Perjeta).

However, researchers are trying to expand the number of HER2 agents available for these patients, Yardley explains, which are being explored in ongoing clinical trials. 

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses unmet treatment needs for patients with HER2-positive breast cancer.

Several developments have been made in the field of HER2-positive breast cancer, particularly with the additions of trastuzumab (Herceptin) and pertuzumab (Perjeta).

However, researchers are trying to expand the number of HER2 agents available for these patients, Yardley explains, which are being explored in ongoing clinical trials. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x